Moreover, our observation that KRAS G12A tumors showed an early recurrence pattern, even in the absence of overt metastatic disease, suggests a unique tumor biology of G12A driving a particularly aggressive behavior from its early stages, rather than poor responsiveness to specific target therapies in advanced settings. This evidence concerns the gene KRAS and metastatic neoplasm.